- Home
- CCEC vs BBNX Comparison
CCEC vs BBNX Comparison
Compare CCEC & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | BBNX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 997.9M |
| IPO Year | 2007 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CCEC | BBNX |
|---|---|---|
| Price | $20.20 | $19.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $25.83 | $24.24 |
| AVG Volume (30 Days) | 5.9K | ★ 933.1K |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | $19.18 | $25.74 |
| Revenue Next Year | $36.89 | $44.51 |
| P/E Ratio | $4.82 | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $16.77 | $8.80 |
| 52 Week High | $23.95 | $32.71 |
Technical Indicators
Market Signals| Indicator | CCEC | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 54.73 |
| Support Level | $19.98 | $9.34 |
| Resistance Level | $21.36 | $20.48 |
| Average True Range (ATR) | 0.45 | 0.95 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 41.71 | 92.95 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.